Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx Posts Increase in Q2 Revenues, Net Loss

NEW YORK (GenomeWeb) - Accelerate Diagnostics today said that revenues for its second quarter rose 46 percent.

According to a document filed with the US Securities and Exchange Commission, for the three months ended June 30, the Tucson, Arizona-based molecular diagnostics company said that revenues increased to $19,000 from $13,000 a year ago, composed entirely of revenues associated with licensing agreements.

The firm's net loss in the quarter was $12.3 million, or $.27 per share, compared to a net loss of $8.2 million, or $.19 per share, in the prior-year period.

Accelerate Diagnostics' R&D spending rose to $7.1 million, up 56 percent from $4.6 million during the second quarter of 2014, driven by new hires and increased purchases of laboratory and instrument engineering supplies to support R&D. Its SG&A costs rose 38 percent to $4.8 million from $3.4 million, driven by increases in salaries and related expenses as the firm ramped up operations.

Accelerate Diagnostics ended the quarter with $35.2 million in cash and cash equivalents.

In mid-day trade Monday on the Nasdaq, shares of Accelerate Dx were down 8 percent at $25.65.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more